| 000 | 01310 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250516070032.0 | ||
| 264 | 0 | _c20120306 | |
| 008 | 201203s 0 0 eng d | ||
| 022 | _a1699-3993 | ||
| 024 | 7 |
_a10.1358/dot.2011.47.11.1688487 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBowles, D W | |
| 245 | 0 | 0 |
_aMulti-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). _h[electronic resource] |
| 260 |
_bDrugs of today (Barcelona, Spain : 1998) _cNov 2011 |
||
| 300 |
_a857-68 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnilides _xadverse effects |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aDrugs, Investigational _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aProto-Oncogene Mas |
| 650 | 0 | 4 |
_aPyridines _xadverse effects |
| 650 | 0 | 4 |
_aReceptor Protein-Tyrosine Kinases _xantagonists & inhibitors |
| 700 | 1 | _aKessler, E R | |
| 700 | 1 | _aJimeno, A | |
| 773 | 0 |
_tDrugs of today (Barcelona, Spain : 1998) _gvol. 47 _gno. 11 _gp. 857-68 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1358/dot.2011.47.11.1688487 _zAvailable from publisher's website |
| 999 |
_c21370147 _d21370147 |
||